SCHEMBL1645633

SCHEMBL1645633

CN1CCN(c2ccc(N)cc2-c2ncco2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
MAPT P10636 4/20 0.50
RAD52 P43351 1/20 0.50
PAK1 Q13153 1/20 0.43
ALDH1A1 P00352 4/20 0.40
HRH4 Q9H3N8 2/20 0.40
POLB P06746 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ADRA2C P18825 3/20 0.40
GAA P10253 3/20 0.40
PTK2B Q14289 3/20 0.40
KMT2A Q03164 3/20 0.40
GFER P55789 1/20 0.40
ESR2 Q92731 1/20 0.40
NCF1 P14598 1/20 0.39
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1647478 0.79 HTT (0.48) KDM4EALDH1A1POLBGAAKMT2A
SCHEMBL4426616 0.74 WDR5 (0.48) MAPTPAK1ALDH1A1GAAKMT2A
SCHEMBL4408061 0.72 KDM4E (0.43) KDM4EMAPTALDH1A1GAAKMT2A
SCHEMBL31463536 0.72 ADRA1A (0.38) MAPTALDH1A1POLBGAAPTK2B
SCHEMBL328223 0.72 MAPT (0.58) KDM4EMAPTRAD52ALDH1A1HRH4
SCHEMBL30346129 0.70 MAPT (0.52) KDM4EMAPTRAD52ALDH1A1HRH4
SCHEMBL26091433 0.70 MAPT (0.52) KDM4EMAPTRAD52ALDH1A1HRH4
SCHEMBL2306566 0.70 ALDH1A1 (0.69) KDM4EMAPTRAD52ALDH1A1POLB
SCHEMBL3947682 0.70 KDM4E (0.51) KDM4EMAPTRAD52ALDH1A1HRH4
SCHEMBL2306346 0.69 SMN1; SMN2 (0.51) KDM4EMAPTALDH1A1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 EP disclosed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 EP disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 WO disclosed
EP-2097413-A1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G Limited (GB) 2009-09-09 EP disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 KDM4E 2593/4885MAPT 1771/4885RAD52 3575/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 KDM4E 1543/4885MAPT 2950/4885RAD52 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.